PneumoSIPProject ID: 651007
Financé au titre de:
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
PneumoSIP – a cost-effective solution for the rapid diagnostic of pneumonia
Détails concernant le projet
Coût total:EUR 71 429
Contribution de l'UE:EUR 50 000
Sujet(s):PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices
Appel à propositions:H2020-SMEINST-1-2014See other projects for this call
Régime de financement:SME-1 - SME instrument phase 1
Despite significant advances in sanitation and medicine, infectious diseases still annually claim in excess of 15 million lives. Community acquired pneumonia (CAP) is a major cause of morbidity and mortality worldwide. Pneumonia is also the leading cause of death in children worldwide. It kills an estimated 1.6 million children under the age of five every year, about 25% of all pediatric deaths around the world – more than AIDS, malaria and tuberculosis combined. In the EU about 3.3 million cases are reported annually with hospitalization rates ranging from 20–50%, meaning that there are about 1 million hospital admissions for CAP per year in the EU. In addition, the growing resistance to antibiotic treatments (>10% in EU), makes pathogen identification and streamlining of antibiotic treatment even more important.
AlphaSIP aims the development of a cost-effective solution for the rapid diagnostic of pneumonia.
Infectious diseases represent the largest segment of the In-Vitro Molecular Diagnostics Market with nearly 50%. It is a big market that is growing fast: $ 5 B with a 14% CAGR. The Point-of-Care Molecular Diagnostics devices market for infectious diseases based on microfluidics has a size of approximately 900 M $ with an even higher growth rate.
PneumoSIP product line is expected to become the main source of growth for the company in the next 5 years. The H2020 SME instrument phase I feasibility study has four main objectives:
- To verify with final users (physicians and lab technicians) the features of the problem.
- To validate and close the first specifications of the product with final users and customers.
- To confirm with updated market studies the future Pn
Contribution de l'UE: EUR 50 000
CALLE CERVANTES 40 - 3P - PC